2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
New findings from the TransEuro cell replacement trial are now published
Parkinson’s is characterised by the progressive loss of dopamine nerve cells (neurons) in an area of the brain associated with movement. Therefore, researchers have been investigating whether cell transplantations have potential to replace the neurons lost, to slow or reverse progression of the condition. What…
Cure Parkinson’s welcomes a new research committee chair
Every research project that Cure Parkinson’s funds must be recommended by our research committee – an independent board of leading Parkinson’s researchers, clinicians, people with Parkinson’s, patient advocates and experts in intellectual property and regulatory affairs, who meet four times a year to evaluate new…
The ASPro-PD trial is now underway
We are excited to announce that the first clinical centre for the ASPro-PD trial opened in February of this year, with the first participant enrolled earlier this month. This follows a delay to the start date due to drug reformulation issues which have now been…
Neurotrophic factors for Parkinson’s: insights from a previous workshop
In 2023, Cure Parkinson’s hosted a workshop where leading experts reviewed the potential of neurotrophic factors as a treatment for Parkinson’s disease. A commentary paper summarising the key outcomes was recently published in the Journal of Parkinson’s Disease. What are neurotrophic factors? Neurotrophic factors, or…
Exenatide-PD3 results published
The full results of the Exenatide-PD3 study, a phase 3 clinical trial of Type 2 diabetes drug exenatide (Bydureon), have now been published. They report that the study unfortunately did not meet its primary or secondary endpoints. The full results of the Exenatide-PD3 study have…